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ABSTRACT 
Introduction: Dystonia is a clinically heterogeneous group of hyperkinetic movement 
disorders. Recent advances have provided a better understanding of these conditions which 
significant clinical impact.  
Sources of data: Peer reviewed journals and reviews. PubMed.gov.  
Areas of agreement: a recent consensus classification, including the assessment of 
phenomenology and identification of the dystonia syndromes, has provided a helpful tool for 
the clinical assessment. New forms of monogenic dystonia have been recently identified.  
Areas of controversy: despite recent advances in the understanding of dystonia, treatment 
remains symptomatic in most patients.  
Growing points: recent advances in genetics have provided a better understanding of the 
potential pathogenic mechanisms involved in dystonia. Deep brain stimulation has shown to 
improve focal and combined forms of dystonia and its indications are constantly expanding.   
Areas timely for developing research: growing understanding of the disease mechanisms 
involved will allow the development of targeted and disease-modifying therapies in the 
future.   
  
INTRODUCTION 
Since Oppenheim coined the term “dystonia musculorum deformans” in 1911, the definition 
of dystonia has been a subject of debate and controversy.1 It refers to a group of conditions 
defined by the nature of the hyperkinetic movement disorder but with highly heterogeneous 
clinical presentations and underlying aetiologies.2 The diagnosis of dystonia is purely based 
on the clinical phenomenology and it is considered to be one of the most poorly recognized 
movement disorders even among neurologists. Recent advances in its clinical classification, 
genetics and underlying pathophysiology have provided a better understanding of this 
condition and important tools for the clinician to guide diagnosis and management.  
       
DEFINITION, PHENOMENOLOGY AND CLINICAL ASSESSMENT  
A revised definition of dystonia has recently been proposed after a consensus agreement by 
international experts.1 Dystonia is a movement disorder characterized by sustained or 
intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or 
both. Dystonic movements are typically patterned, twisting, and may be tremulous. Dystonia 
is often initiated or worsened by voluntary action and associated with overflow muscle 
activation. 
The underlying hallmark of dystonia is involuntary sustained muscle contractions producing 
abnormal postures or movements. However, there is a great phenotypic variability which 
might contribute to its under recognition in mild or atypical cases. Given the absence of 
specific diagnostic tests, the diagnosis remains clinical and recognition of the multiple clinical 
manifestations of this hyperkinetic movement disorder is crucial for a correct diagnosis. Key 
clinical features and additional clinical signs that can be useful diagnostic clues in cases with 
atypical phenomenology are summarised in table 1. In most cases dystonia combines 
sustained postures, as well as discontinuous and irregular contractions leading to dynamic 
postures and intermittent movements. Sometimes these movements can have tremor-like 
characteristics (oscillatory and seemingly rhythmical though often inconstant) referred to as 
dystonic tremor. Postures and movements in dystonia are patterned: they are usually 
repetitive, stereotyped and predictable, involving the same body part and directionality. 
Dystonia is often triggered or worsened by voluntary actions including movements and 
sustained postures against gravity. Severity of the symptoms can be also modified by 
sustaining the affected body part in different positions: symptoms may worsen when the 
body part is held against the direction of the dystonic movement (eg, turning the head to the 
left in right laterocollis) and may temporarily resolve when the body part is positioned in the 
maximum direction of the movement (eg, turning the head to the right in right laterocollis; this 
position is called null point). Sensory tricks (or gestes antagonistes) are voluntary simple 
manoeuvres not consisting in a forceful resistance of the dystonic movements (typically 
described in cervical dystonia as a light touch to the face or the chin), that can alleviate 
temporarily the symptoms. Sometimes dystonia is only present when performing a specific 
motor skill (task-specific dystonia) such as writing in writers’ cramp/dystonia or musicians’ 
dystonia. Dystonic contractions in the affected limb can also be triggered by contralateral 
motor tasks (eg, finger tapping in the non-affected hand can cause dystonic contractions in 
the contralateral arm) called mirror dystonia. Overflow refers to the spread of involuntary 
muscle contractions to an unaffected (usually contiguous but also contralateral) body part 
distinct from the primary site of dystonia. 
Although in most cases recognition of dystonia is easily achieved by clinical examination, in 
some cases multisurface (mapping) electromyography (EMG) may be a useful 
complementary diagnostic tool in differentiating dystonia from other movement disorders 
(mainly tremor and myoclonus) by detection of the pattern of muscle activation (agonist-
antagonist muscle coactivation, phasic and tonic activation, mirror dystonia and sensory 
tricks).3 It may also be useful in identification of dystonic muscles to guide the treatment as 
discussed later. 4, 5 Patients with dystonia can present with asymmetric rest tremor, 
sometimes with pill-rolling characteristics, hypomimia, increased limb tone without rigidity, 
reduced arm swing and even slow repetitive movements but without true bradykinesia.6 The 
nigrostriatal system is spared in patients with dystonia and a normal dopaminergic 
transporter imaging may also be useful diagnostic tool in certain cases to differentiate 
dystonia from patients with degenerative parkinsonism.7  
Isolated dystonia has classically been considered a purely motor condition but, as in other 
movement disorders, the presence of multiple other associated non-motor symptoms has 
been recently recognised with important clinical implications in disability and quality of life. 
These include sensory symptoms such as discomfort in that body part prior to development 
of dystonia, sensory tricks, pain or photosensitivity in blepharospasm, neuropsychiatric 
abnormalities such as depression, and sleep disturbances.8, 9  
   
CLASSIFICATION 
To incorporate recent advances in dystonia and address some of the limitations of previous 
classifications, an international consensus committee proposed a new classification system 
in order to facilitate diagnosis and treatment, but also a basis for development of research 
and pathogenesis.1 The new classification scheme has two distinct axes: clinical 
characteristics (axis I) and aetiology (axis II) (Table 2).  
 Axis I: clinical characteristics. They  include age at onset, body distribution, temporal 
pattern and associated features with different subgroups. The aim of this axis is the 
recognition of the phenotypic characteristics of the different dystonic syndromes.  
 Axis II: etiology. It contains two non-mutually exclusive subgroups: presence of 
identifiable nervous system pathology and pattern of acquisition. The aim of this axis 
is to classify dystonia according to common biological and pathophysiological 
mechanisms. This is a constant evolving area which will require regular update as 
advances improve the understanding of the underlying mechanisms.  
 DIAGNOSTIC APPROACH  
Owing to the clinical heterogeneity and the growing number of causes, an accurate 
diagnosis of dystonia can be sometimes challenging. Classically movement disorder 
specialists have used a syndromic approach to diagnose dystonia, targeting diagnostic tests 
after matching the clinical features of the patient to known diseases. This approach relies in 
the clinician’s expertise and the use of growing exhaustive lists of the causes of dystonia 
which might not be practical in clinical settings for the non-experts. Therefore more dynamic 
algorithms have been suggested 1, 10, 11 where classification and characterization of the main 
clinical features (using clinical characteristics from axis I of the classification) should guide 
the clinicians in the diagnostic decision making process, tailor the diagnostic tests and avoid 
unnecessary investigations. A suggested diagnostic pathway is proposed in Figure 1. Ideally 
an etiological diagnosis of the dystonic syndrome (axis II of the classification) should be 
reached after taking together the definition of the clinical characteristics and the results of 
the ancillary investigations. Following the current classification, we present the most 
common forms of dystonia based on their etiology and describe their most frequently 
associated clinical presentations.   
 
IDIOPATHIC DYSTONIA WITHOUT EVIDENCE OF NERVOUS SYSTEM PATHOLOGY  
Cervical dystonia  
Cervical dystonia is the most common form of focal dystonia with a prevalence of 5 cases 
per 100000, symptom onset in the fifth decade and 2:1 female predominance.12 It presents 
most frequently with abnormal postures including lateral tilting (laterocollis) and turning 
(torticollis) of the head, head tremor or a combination of both. Sensory tricks are reported in 
up to 80% of patients involving usually light touch to the lower face or neck.13 Palpation 
usually reveals increased muscle tone and hypertrophy of the muscles involved. Cervical 
dystonia commonly progresses within the initial few years before the symptoms stabilise.   
 
Blepharospasm 
Blepharospasm is characterised by bilateral synchronous spasms of the orbicularis oculi 
muscle resulting in repeated blinking and forceful closure of the eyelids with various degrees 
of functional blindness in most severe cases. Onset is usually insidious in the sixth decade 
with female predominance and associated with sensory symptoms including dry eyes, 
photosensitivity and sensory tricks. 14 Blepharospasm has the highest risk of spread among 
focal dystonias (around a third of patients) usually happening within the first few years of 
onset and involving lower face and jaw muscles (Meige syndrome).15    
 
Oromandibular dystonia 
Oromandibular dystonia affects the jaw muscles more common manifesting as closing-jaw 
dystonia with additional involvement of tongue and pharyngeal muscles. Typically dystonic 
spasms worsen during talking, chewing or eating and may result in impairment of speech 
and feeding in severe cases.16   
 
Laryngeal dystonia (spasmodic dysphonia) 
Laryngeal dystonia is a rare task-specific speech dystonia characterised more commonly by 
involuntary closure of the vocal cords (adductor spasmodic dysphonia) causing effortful, 
strained, strangulated voice interrupted by phonatory breaks. Voice is typically worse when 
speaking but it may improve with singing, whispering, shouting or changing the pitch. It 
usually presents in the fifth decade with a slight female predominance. Other less common 
manifestations include abductor spasmodic dysphonia (resulting in a whispery voice 
interrupted by breathy breaks especially with consonants), voice tremor, stridor, 
dyscoordinate breathing, paroxysmal cough, hiccups, and sneezing.17     
 
Task-specific dystonia 
Task-specific dystonia is a form of isolated focal dystonia that occurs only during the 
performance of highly skilled, overlearned motor tasks. The most common forms are writers’ 
dystonia and musicians’ dystonia but it can involve any body part and tasks, including facial 
muscles in wind instrument players, golfers’ yips in the upper limbs or foot dystonia in 
dancers.18 Symptoms usually start insidiously during the fourth decade perceived initially as 
loss of fine motor control associated to a feeling of tightness that subsequently progresses to 
evident dystonic posturing. Dystonic contractions can remain highly task-specific but in a 
significant proportion of patients symptoms may develop during performance of other fine 
movements different from the initial motor tasks and may spread to the contralateral hand.19  
Examination should look for any dystonic contractions while performing specific triggering 
motor tasks but also body parts involved should be observed while at rest, holding different 
positions and performing other unrelated common motor tasks looking for mirror dystonia, 
overflow and null points.18 Some patients may show additional increased tone, reduced arm 
swing and effortful repetitive movements in the involved limb but without decrement of the 
amplitude of the movement (bradykinesia).   
 
INHERITED DYSTONIA WITHOUT EVIDENCE OF NERVOUS SYSTEM PATHOLOGY 
Recent advances in the genetic of dystonia have led to the identification of a growing 
number of new forms of monogenic dystonia and expansion of the associated phenotype in 
both, isolated and combined dystonia syndromes.20, 21 They have also provided better 
understanding of the potential pathogenic molecular pathways including dysfunction in the 
endoplasmic reticulum-associated protein degradation and nuclear envelope systems, 
vesicle/protein trafficking in synaptic transmission and involvement of cell cycle control and 
transcriptional regulation.22 
 
Isolated dystonia 
DYT1 and DYT6 are the most common genetic causes of isolated dystonia. Both forms are 
autosomal dominant with reduced penetrance due to mutations in TOR1A (DYT1) and 
THAP1 (DYT6) genes.23, 24 DYT1 is classically associated with early-onset limb dystonia that 
gradually spreads to generalised dystonia while DYT6 typically remains segmental involving 
upper limbs and craniocervical regions with prominent laryngeal involvement.  
Since the use of next-generation sequencing techniques, additional genes have been 
associated to adult-onset dominant forms of isolated dystonia: mutations in CIZ1 gene 
(DYT23) have been associated with cervical dystonia,25 mutations in ANO3 gene (DYT24) 
with cervical dystonia with prominent tremor,26 and GNAL gene mutations (DYT25) with 
craniocervical dystonia.27 All three conditions are thought to be very rare and genetic testing 
is not commercially available or clinically recommended but mutations of these genes have 
also been described in cases without family history and may be responsible for a proportion 
of sporadic cases. Recently, heterozygous variants in the KMT2B (MLL4) gene have been 
identified in individuals with familial dystonia with prominent cervical, cranial and laryngeal 
dystonia.28 
 
Combined dystonia syndromes   
Dopa-responsive dystonia  
The term dopa-responsive dystonia (DRD) encompasses a clinically and genetically 
heterogeneous group of conditions with a classic phenotype of early-onset lower limb 
dystonia with diurnal fluctuation and excellent and sustained response to levodopa. The 
most common and best characterised DRD is an autosomal dominant form due to mutations 
in the GTP cyclohydrolase 1 gene (DYT5a also known as Segawa disease). It typically 
presents as childhood dystonia involving the lower limbs with diurnal fluctuations (worsening 
in the evenings and improvement with sleep) causing gait disturbances that gradually 
progresses to segmental or generalised dystonia. Other atypical features include brisk 
reflexes and extensor plantar response which may lead to the misdiagnosis of cerebral 
palsy, parkinsonism in adult-onset presentations, oculogyric crisis, myoclonus and 
neuropsychiatric symptoms such as anxiety, depression, sleep disturbances and obsessive-
compulsive disorders.29 Once the response of the symptoms is established after a levodopa 
trial, the diagnosis can be confirmed using genetic testing for most common GTP 
cyclohydrolase 1 gene mutations. However commercially available genetic testing is not 
comprehensive and in cases with negative results but suggestive phenotype, additional 
analysis of cerebrospinal fluid levels of neurotransmitters and phenylalanine loading test 
may be useful to reach a diagnosis.30 Dopamine transporter imaging shows normal results in 
DRD and may be useful in differentiating it from idiopathic Parkinson’s disease (PD). 
However, adult-onset cases of degenerative parkinsonism with nigrostriatal degeneration 
(and abnormal dopamine transporter imaging) have been described in families with DRD 
secondary to rare GTP cyclohydrolase 1 variants and the authors suggested that some 
mutations should be considered as risk factors for PD.31 Symptoms of DRD have a dramatic 
and sustained response to small doses of levodopa (50-200 mg/day) even if the treatment is 
delayed for many years, and patients do not develop motor complications usually seen in 
patients with PD.   
Other rare forms of DRD can be caused by recessive mutations in other genes encoding 
enzymes involved in the biosynthesis of dopamine such as tyrosine hydroxylase, sepiapterin 
reductase and PTP synthase. These rare recessive forms usually present at an earlier age 
with a more severe phenotype and other associated neurological features (including 
cognitive impairment, hypotonia, seizures) but show similar good response to low doses of 
levodopa.30  
  
Myoclonus dystonia syndrome 
Myoclonus dystonia syndrome (MDS) is a rare condition with onset in the first two decades 
of life with a typical clinical pattern of alcohol-responsive upper body myoclonus with 
associated dystonia in two thirds of patients. Myoclonus is usually the main and most 
disabling symptom while dystonia is mild and manifests as cervical dystonia or writer’s 
cramp. Psychiatric disorders including depression, anxiety, panic attacks and obsessive-
compulsive behaviour are commonly reported.32 MDS is inherited in an autosomal dominant 
manner and mutations in the epsilon-sarcoglycan gene (SGCE; DYT11) are responsible in 
less than half of the cases with reduced penetrance and maternal imprinting.33 Recently, 
mutations in the KCTD17 gene have been associated with MDS34 and some cases may be 
secondary to mutations in genes classically related to other dystonic syndromes (TOR1A, 
ANO3 and DRD associated genes) but also related to other genes yet to be identified.    
      
Rapid-onset dystonia parkinsonism 
Rapid-onset dystonia parkinsonism (DYT12) is a rare disorder that typically presents after 
triggering factors and progresses rapidly over hours to days with involuntary movements 
characterised by dystonia, bradykinesia and postural instability without tremor. Potential 
triggers include physical exertion, overheating, infections, alcohol binging, mild head trauma 
or emotional stress. Sometimes mild limb dystonia can precede the abrupt onset of the 
symptoms. Symptom onset is in childhood or early adulthood, they usually have a 
rostrocaudal gradient with prominent bulbar involvement and they stabilise after the initial 
progression with little improvement.35 Psychiatric disorders including anxiety, depression, 
obsessive-compulsive behaviour and psychosis have also been reported.36 Rapid-onset 
dystonia parkinsonism is inherited in an autosomal dominant manner but commonly presents 
de novo caused by mutations in the ATP1A3 gene, which is also associated with alternating 
hemiplegia of childhood and more recently to paroxysmal dyskinesias and CAPOS 
syndrome (Cerebellar ataxia, Areflexia, Pes cavus, Optic atrophy and Sensori-neural hearing 
loss).37  
 
Paroxysmal dyskinesias 
Paroxysmal dyskinesias are a heterogeneous group of conditions characterised by recurrent 
episodes of hyperkinetic movements including dystonia. Three different forms are 
recognised although there is some clinical and genetic heterogeneity.38, 39  
The most common subtype is paroxysmal kinesigenic dyskinesia (PKD) where attacks start 
in childhood and are triggered by sudden movements (such as standing from a sitting 
position or running from walking). Attacks can be preceded by an abnormal sensation, 
duration is short (usually < 1 min) but can happen multiple times per day with a peak in 
puberty. Symptoms usually respond to antiepileptics and carbamazepine is the drug of 
choice.38 Mutations in the PRRT2 gene account for the majority PKD cases and can also be 
associated to epilepsy, ataxia, hemiplegia and migraine.39 In paroxysmal non-kinesigenic 
dyskinesia (PNKD) attacks last longer (usually several minutes), are triggered by coffee, 
alcohol or strong emotions but they are more infrequent. PNKD has been associated with 
mutations in the MR-1 gene, also known as PNKD gene. Paroxysmal exercise-induced 
dyskinesia (PED) is thought to be the rarest form, where attacks are triggered by prolonged 
exercise usually lasting for several minutes. Mutations in the SLC2A1 gene, which encodes 
the glucose transporter 1 (GLUT 1), are responsible for PED and it can be associated to 
migraine, hemiplegia, ataxia and epilepsy.39 
 
ACQUIRED DYSTONIA 
 Acquired dystonia is a large and heterogeneous group of disorders.  
Cases of dystonia secondary to structural lesions such as perinatal brain injury, central 
nervous system infections, brain tumours or vascular events commonly show abnormal 
findings on neuroimaging. They usually present as either hemidystonia or focal limb 
dystonia.  
Drug-induced is a common form of dystonia and can present as an acute reaction to 
medications such as levodopa, dopamine agonists, dopamine-receptor blocking drugs, 
anticonvulsants and serotonin reuptake inhibitors, or as a persistent tardive syndrome after 
prolonged exposure to antipsychotics. Dystonia can also be caused by the toxic effect of 
manganese, cobalt, carbon monoxide, carbon disulphide, cobalt, methanol and other 
chemicals.  
Dystonia can be part of the presentation of acquired neurodegenerative disorders although 
in these cases other neurological signs predominate on the examination. Examples include 
foot dystonia in PD, anterocollis in multiple system atrophy, blepharospasm in progressive 
supranuclear palsy or dystonic arm in corticobasal degeneration. 
       TREATMENT 
Management of dystonia is typically symptomatic and oral medications, chemodenervation 
with botulinum toxin (BT) and surgical interventions are the three mainstays. Usually, 
symptomatic treatment is only partially effective and should not only focus on the 
management of the movement disorder but also other aspects of the condition. A 
multidisciplinary approach including physical and psychological therapies should be 
considered in order to improve quality of life and specific tools to assess the impact of the 
treatment have been developed.40 The choice of treatment will depend mainly on age, 
severity and distribution of the symptoms. 41 For patients with multifocal or generalised 
dystonia oral drugs are commonly the initial treatment although efficacy may only be partial 
and side effects may limit their use particularly in adult patients. On the other hand, focal or 
segmental dystonia are usually initially managed with botulinum toxin injections. Surgical 
procedures are generally considered in severe medication-refractory dystonia, particularly 
those with a genetically proven condition with generalised distribution, although its 
indications are constantly expanding.     
The list of combined dystonia syndromes with available specific disease treatment is 
constantly expanding. It is essential not to miss them as a timely treatment might slow 
disease progression or even revert the symptoms. Wilson’s disease and DRD are the most 
common examples but the list also includes other metabolic disorders such as GLUT1 
deficiency, organic acidurias, lysosomal storage disorders or brain manganese 
accumulation.42 
    
Oral medications 
Pharmacological treatment is largely guided by empirical trials and personal experience as 
well-designed studies are scarce.43 
Dopaminergic therapy, and particularly levodopa, is the specific treatment for DRD and 
patients have a dramatic and sustained response to small doses (50-200 mg/day) even if the 
treatment is delayed for many years.30 An empirical trial with levodopa for 1 month is 
recommended in any dystonia with onset in childhood and young adulthood to rule out DRD 
even when the presentation lacks some classical features. Patients with other forms of 
dystonia may also benefit of treatment with levodopa though the response is often only 
minimal.  
Anticholinergics are considered the first line drug in patients with generalised dystonia and 
owing to the evidence from a double-blinded placebo-controlled trial, trihexyphenidyl is the 
preferred agent.44 It should be started at 1mg/d and the dose slowly titrated to avoid side 
effects which may limit its benefit and include drowsiness, confusion, memory impairment 
and dry mouth. Therapeutic dose ranges from 6-40mg/d and children usually tolerate much 
higher doses having a better chance of benefit. Baclofen is usually better tolerated (side 
effects include sedation, dizziness and cognitive impairment) and high doses (therapeutic 
dose 40-120mg/d divided in 3 doses) may be beneficial especially in children with spasticity 
associated to dystonia. Dopamine depleting drugs such as tetrabenazine (starting dose 
12.5mg/d; therapeutic dose 50-150mg/d divided in 3 daily doses) has also shown some 
improvement particularly in those with tardive dystonia. Potential side effects include 
drowsiness, depression and parkinsonism. Benzodiazepines (clonazepam: starting dose 
0.5mg/d, therapeutic dose 1-6mg/d) may also be beneficial particularly as an adjunctive 
therapy.   
 
Botulinum toxin 
BT is the treatment of choice in most patients with focal or segmental dystonia including 
cervical dystonia, blepharospasm, oromandibular dystonia, laryngeal dystonia and writer’s 
cramp.45, 46 BT causes a chemodenervation of the muscle by interfering with the release of 
acetylcholine from the nerve terminals into the neuromuscular junction. As a consequence of 
changes in the peripheral sensory input, BT could also have a therapeutic effect on the 
central nervous system by modifying the excitability and plasticity of central pathways.47 
There are two different serotypes with several available formulations without marked 
differences in efficacy or side effects:48 serotype A (onabotulinumtoxinA, 
abobotulinumtoxinA, incobotulinumtoxinA) and serotype B (incobotulinumtoxinB). 
Improvement usually starts a few days after the injections with a peak in 4-6 weeks. The 
effect gradually wears off but the benefit usually persists for 12-16 weeks, so the injections 
are repeated 3-4 times per year. The dose, selection of muscles and number of injection 
sites should be highly individualised based on severity, distribution of the symptoms, 
response to previous injections and bulk of the muscles. Identification of dystonic muscles is 
usually through careful clinical examination, but in complex cases use of ultrasound or 
electromyography can improve target muscle selection.4, 5 Adverse effects are local and 
temporary generally due to diffusion of BT to adjacent structures: ptosis, dry eyes and 
diplopia in blepharospasm, dry mouth, neck weakness and dysphagia in cervical dystonia, 
and excessive weakness in limb dystonia. Most cases of reduced response to BT treatment 
are due to suboptimal injection schemes (inappropriate BT dose or muscle target selection) 
although in a proportion of secondary non-responders development of neutralising 
antibodies may block BT action.49 
 
Deep brain stimulation 
Deep brain stimulation (DBS) of the globus pallidus internus (GPi) has become the preferred 
surgical procedure and ablative and denervation techniques have been largely abandoned. 
GPi DBS has been shown to be effective in the treatment of isolated generalised, segmental 
and medication-refractory cervical dystonia 50, 51 with better response in those with DYT1 
mutations. Patients with dystonia have a delayed clinical response with the phasic 
component of dystonia usually improving within weeks while dystonic postures may take 
several months or even longer. Risks are due to the surgical procedure (but lower than for 
other patients undergoing DBS as dystonia patients are younger), complications of the 
device (infections, lead breakage) and stimulation-related which can be resolved with 
modification of the settings (dysarthria, parkinsonism). Other focal isolated dystonias 
(writer’s cramp), combined dystonias (myoclonus dystonia syndrome), dystonia associated 
to PD and tardive dystonia may also benefit from GPi DBS. There is a less favourable 
response in those with dystonia secondary to structural brain lesions (eg; cerebral palsy).52     
 
Other therapies 
Physical therapies are aimed at maintaining a full range of motion and prevent contractures. 
Several interventions including rehabilitation, physical devices, sensori-motor training and 
behavioural therapy have shown to improve dystonia, mainly as adjunctive therapies, 
although the supporting evidence to recommend them is limited.53 
Recent advances in the understanding of the pathophysiological mechanisms of dystonia 
have prompted the assessment of transcranial magnetic stimulation as a potential treatment 
for dystonia. Results have been conflicting and heterogeneity of the protocols makes difficult 
to draw any conclusions although this is an area of active research.54      
 
CONCLUSIONS 
Recognition of the dystonia phenomenology and identification of the dystonia syndrome 
using the consensus classification is essential for an accurate clinical diagnosis which then 
guides potential therapy. Symptomatic treatment with oral medication and BT should be 
highly individualised based on severity and distribution of the symptoms and GPi DBS is a 
successful option for an increasing number of patients. Recent advances in genetics, 
neurophysiology and imaging studies have provided a better understanding of the underlying 
pathophysiology of dystonia. Further research on these areas will allow developing disease-
modifying therapies in the future. 
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TABLES 
Table 1. Motor phenomenology in dystonia. 
Clinical feature Description 
Dystonic posture / 
movement 
A body part is flexed, extended or twisted along its longitudinal 
axis with associated sensation of rigidity and traction. Postures 
can be sustained or dynamic. Movements can be fast or slow, 
continuous or intermittent.  
Dystonic tremor Oscillatory and seemingly rhythmical though often inconsistent 
and irregular dystonic movements. Dystonic tremor is often 
exacerbated by positioning the affected area against the 
maximum direction of the pull.   
Patterning Postures and movements are stereotyped, involving the same 
body part and with a characteristic directionality.  
Voluntary action Dystonia is typically influenced by voluntary actions and 
sometimes it is only activated by performing a specific motor 
task (task-specific dystonia) 
Overflow Unintentional muscle contraction that accompanies the primary 
site of dystonia but is anatomically distinct (usually contiguous 
but also contralateral) 
Mirror dystonia Dystonic symptoms triggered in the affected limb when the 
unaffected limb performs a motor task 
Null point Resolution of dystonic symptoms when the body part affected is 
placed in the maximum direction of the pull 
Alleviating 
manoeuvres (geste 
antagoniste, 
sensory trick) 
Simple voluntary manoeuvres not consisting in a forceful 
opposition of the movement that can temporarily minimize 
dystonic symptoms 
Pseudodystonia Abnormal movements and/or postures that do not share the 
clinical phenomenology of dystonia and are caused by a known 
or presumed cause with a different pathophysiological basis. 
 
  
Table 2. New consensus classification of dystonia according to clinical and etiological 
features. 
Axis I: clinical characteristics 
Age at onset - Infancy (0-2 years) 
- Childhood (3-12 years) 
- Adolescence (13-20 years) 
- Early adulthood (21-40 years) 
- Late adulthood (>40 years) 
Body distribution - Focal: one body region (blepharospasm, cervical dystonia) 
- Segmental: >2 contiguous body regions (blepharospasm + 
oromandibular dystonia) 
- Multifocal: >2 non-contiguous body regions  
- Hemidystonia: one body side  
- Generalised: trunk and 2 other sites 
Temporal pattern - Disease course: static vs progressive 
- Variability: persistent, action-specific, diurnal fluctuations, 
paroxysmal 
Associated features - Isolated (may include tremor) 
- Combined with other movement disorder 
- Co-occurring neurological or systemic manifestations 
Axis II: etiology 
Nervous system 
pathology 
- Degenerative 
- Structural (static) lesions 
- No evidence of degenerative or structural lesions 
Mode of acquisition - Inherited: autosomal dominant, autosomal recessive, X-
linked recessive, mitochondrial 
- Acquired (known cause): perinatal brain injury, infection, 
drugs, toxins, vascular, neoplastic, brain injury, 
psychogenic 
- Idiopathic (unknown cause): sporadic, familial 
 
  
FIGURE CAPTION 
Figure 1. Diagnostic algorithm of dystonia  
 
